Swiss GO Trial Group
Additional Information
Events
Planned conferences / workshops / meetings as well as scientific contributions / publications
For the latest information see below and Join in!
February 2022
DKF Tag der Klinischen Forschung, Universitätsspital Basel, 10.2.2022
Abstract/Poster:
ENGOT-ov54/Swiss-GO-2/MATAO: MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer - A Swiss investigator initiated RCT on re-purposing of a generic drug.
Presenter: Pamela McLaughlin
Actual: Annemarie Karrasch Forschungspreis: Preisverleihung 2022 Prof. Dr. Viola Heinzelmann-Schwarz
March 2022
MATAO CH-D-A Investigator (PI) Meeting, Basel 5.-6- März 2022 (virtuell)
SAKK In-between Meeting I: 10.03.2022, 16.00-18.00h (virtuell)
April 2022
AACR Annual Meeting, 8.4.-13.4.2022 (New Orleans, USA), Abstract submission closed / None submitted
Spring ENGOT General Assembly: April 28-29, 2022 - Hotel Marriott, Copenhagen, Denmark
May 2022
SAKK Semi-Annual Meeting: 05.05.–06.05.2022 in Zurich (final decision not before 05.03.22)
June 2022
- Swiss-GO Mitgliederversammlung (geplant Anfang Juni)
- Swiss-GO General Member assembly (planed for begiining of June 2022)
- ASCO Annual Meeting 2022, 3.6-7.6.2022 (Chicago, USA), Abstract submission deadline: 15.02.2022
- SGGG Jahresversammlung, 23.6.-25.6.2022 (St.Gallen), Abstract-Einreichungsfrist: 10.02.2022 (17 Uhr)
July 2022
August 2022
September 2022
SAKK In-between Meeting II: 22.09.2022, 16.00-18.00h (virtuall)
October 2022
- Autumn ENGOT General Assembly: October 6-7, 2022 - Hotel H10 Ku´Damm, Berlin, Germany
- DGGG, 64. Jahresversammlung, 12.10.-15.10.2022 (München), Abstract-Einreichungsfrist: 15.05.2022
November 2022
SAKK : Semi-Annual Meeting I 16.11.2022,Congress Center Basel, Messeplatz 21, 4058 Basel, 13.30-17h
December 2022
Swiss-GO Executive Board Meneber meeting 02. 12.2022, virtual (Monday, 19pm)
Planned for 2023
- SAKK: In-between I: 2.03.23, 9.00-11.00 (virtual)
- ENGOT General Assembly: March 9-10, 2023 - Madrid, Spain
- SAKK: Semi-Annual Meeting I: 12.05.23, 8.30-12.00 (Bern)
- SAKK: In-between II: 28.09.23, 9.00-11.00 (virtual)
Planned conferences / workshops / meetings as well as scientific contributions Year 2021 (Status 31.01.2022)
Conferences:
- Festival of Biologics: World Clinical Trials Congress Basel 2022 November 2nd, 2022
Panel discussion : "Panel Discussion: How has the pandemic redefined decentralized clinical trials?"
Speakers: Pamela Mclaughlin, Clinical Trial Manager at Swiss GO Trial Group and Clinical Chemist,University Hospital Basel, Laura Galuchie,Sr Director, Global Trial Management, MSD and Benoit Marchal, Project Manager, Partners for patients - ASCO Annual Meeting 2021, 4.6.-8.6.2021 (Chicago, USA)
Abstract/Poster:
ENGOT-ov54/Swiss-GO-2/MATAO including LOGOS (Low Grade Ovarian cancer Sub-study): MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer; a randomized, double-blinded, placebo-controlled, multi-center phase III Trial
Viola A. Heinzelmann-Schwarz, Christian Kurzeder, Seraina Schmid, Natalie Gabriel, Andreas Mueller, Mathias K. Fehr, Christian Marth, Andreas Du Bois, Maximillian Klar - ASCO Annual Meeting 2021, 4.6.-8.6.2021 (Chicago, USA)
Abstract/Poster:
Health concerns in long-term survivors with ovarian cancer: Results of Expression VI–Carolin meets HANNA–Holistic Analysis of Long-term survival with Ovarian Cancer—The international NOGGO, ENGOT and GCIG survey
Hannah Woopen, Maren Keller, Ioana Braicu, Dario Zocholl, Joanna Baum, Petra Krabisch, Tamara Boxler, Pauline Wimberger, Catarina Madroñal, Marta Gil-Martin, Vesna Bjelic-Radisic, Sinisha Trpchevski, Eleftherios Pierre Samartzis, Viola A. Heinzelmann-Schwarz, Patriciu Achimaș-Cadariu, Paul Kubelac, Mehmet Ali Vardar, Marcin Andrzej Jedryka, Ignace Vergote, Jalid Sehouli - ENGOT Meeting 2021, 30.9-1.10. 2021 (Kopenhagen, DK)
Abstract:
ENGOT-ov54/Swiss-GO-2/MATAO including LOGOS (Low Grade Ovarian cancer Sub-study): MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer; a randomized, double-blinded, placebo-controlled, multi-center phase III Trial
Viola A. Heinzelmann-Schwarz, Christian Kurzeder, Seraina Schmid, Natalie Gabriel, Andreas Mueller, Mathias K. Fehr, Christian Marth, Andreas Du Bois, Maximillian Klar - GCIG Autumn Meeting 2021, 8.11.-19.11.2021 (virtual)
Abstract:
ENGOT-ov54/Swiss-GO-2/MATAO including LOGOS (Low Grade Ovarian cancer Sub-study): MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer; a randomized, double-blinded, placebo-controlled, multi-center phase III Trial
Viola A. Heinzelmann-Schwarz, Christian Kurzeder, Seraina Schmid, Natalie Gabriel, Andreas Mueller, Mathias K. Fehr, Christian Marth, Andreas Du Bois, Maximillian Klar
